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Phase I Trial of Motexafin Gadolinium in Combination with
Docetaxel and Cisplatin for the Treatment of Non-small
Cell Lung Cancer
William N. William, Jr., MD,* Ralph G. Zinner, MD,* Daniel D. Karp, MD,* Yun W. Oh, MD,*
Bonnie S. Glisson, MD,* See-Chun Phan, MD,† and David J. Stewart, MD*
Introduction: Motexafin gadolinium is a novel antineoplastic drug
that disrupts cancer cell antioxidant systems, thus contributing to
cellular death. In patients with lung cancer, motexafin gadolinium
has been shown to increase the time to neurologic progression when
given in combination with whole-brain radiotherapy in randomized
phase III studies. Preclinical data suggest that this drug might also
enhance the antineoplastic effects of chemotherapy.
Methods: In this one-arm, open label, phase I, dose-escalation
study, we administered docetaxel (75 mg/m2), cisplatin (75 mg/m2),
and motexafin gadolinium every 3 weeks to patients with metastatic
non-small cell lung cancer. Twenty-one patients were treated at one
of four motexafin dose levels.
Results: The maximal tolerated motexafin dose was 10 mg/kg on
day 1 of a 3-week cycle. Dose-limiting toxicities consisted of febrile
neutropenia, hypertension, myocardial ischemia, and pneumonitis/
pulmonary infiltrates. Other common grade 3–4 adverse events
across all cohorts that did not appear to be exacerbated by motexafin
gadolinium included granulocytopenia, fatigue, dehydration, nausea,
and vomiting. Two episodes of myocardial ischemia and one sudden
death of unknown cause were observed. Response rates were partial
response (10%), stable disease (60%), and disease progression
(30%).
Conclusions: The regimen studied was tolerable and showed activ-
ity in patients with metastatic non-small cell lung cancer. The
recommended doses for future phase II trials are motexafin gado-
linium 10 mg/kg, docetaxel 75 mg/m2, and cisplatin 75 mg/m2
intravenously on day 1 every 3 weeks. Caution is advised in patients
with a history of cardiovascular disease.
Key Words: Motexafin gadolinium, Cisplatin, Docetaxel, Non-
small cell lung cancer.
(J Thorac Oncol. 2007;2: 745–750)
Motexafin gadolinium (MGd) is a member of a class ofrationally designed porphyrin-like molecules called
texaphyrins. Studies in humans1,2 and mice3,4 have dem-
onstrated that, like naturally occurring porphyrins, MGd
exhibits a preferential biodistribution to cancer cells, with
an eightfold greater concentration in tumors than in sur-
rounding tissues.5
Texaphyrins exhibit catalytic activity by accepting
electrons from compounds that possess a sufficiently negative
reduction potential. In the presence of oxygen, such electron
transfer results in superoxide formation and regenerates the
texaphyrin by a process referred to as redox cycling.6 Super-
oxide, together with other reactive oxygen species such as
hydrogen peroxide, may damage cellular DNA through oxi-
dative stress-induced destruction of pyrimidine and purine
bases and single-strand breaks and oxidation of protein thiols
and lipids, ultimately triggering apoptosis in a number of
cancer cells.7 The glutathione redox system and redox regu-
latory proteins, such as thioredoxin reductase and thiore-
doxin, are responsible for protecting cells from toxic oxidant
damage by maintaining proper redox balance among many
cellular molecules.8 Interestingly, MGd also inhibits thiore-
doxin reductase activity.9,10 All in all, MGd seems to disrupt
the cellular antioxidant system in several different ways. The
distinctive redox perturbations of tumors and the unique
biodistribution of MGd may render texaphyrins a novel class
of antineoplastic selective cytotoxic drugs with potentially a
more favorable side effects profile.
A series of phase I and II clinical trials in humans with
a variety of cancer types have established the safety and
tolerability of MGd in single or multiple doses given con-
comitant with radiation.1,11 These studies were followed by
the recent completion of two international phase III random-
ized trials of MGd administered daily before whole-brain
radiation therapy (WBRT) versus WBRT alone for patients
with metastatic brain lesions from any solid tumor12 or from
non-small cell lung cancer (NSCLC) exclusively.13 Although
there was no benefit in overall survival among patients treated
with the study drug, the addition of MGd to WBRT delayed
the time to neurologic progression and improved memory and
executive function in patients with NSCLC.12–15 These results
are anticipated to be used for filing to the U.S. Food and Drug
Administration for a new drug application of MGd in com-
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bination with WBRT in patients with brain metastases from
NSCLC.
Preclinical studies also provide a rationale for the
combination of MGd with chemotherapy as a way of enhanc-
ing cytotoxicity.16 Lewis lung carcinoma–implanted mice
treated with MGd in combination with carboplatin, paclitaxel,
bleomycin, doxorubicin, or BCNU exhibited a delay in tumor
growth when compared with animals that received the che-
motherapy agents alone.17 MGd also increased the antitumor
activity of docetaxel in vivo in CD-1 nude mice implanted
with human A549 lung cancer cells.18
We present herein the first phase I trial of the combi-
nation of MGd, cisplatin, and docetaxel for the treatment of
patients with metastatic NSCLC. The primary aims of the
present study were to determine the maximal tolerated dose
(MTD) and the dose-limiting toxicities (DLTs) of this com-
bination in the study population. Tumor response was also
evaluated as a secondary endpoint.
METHODS
This was a one-arm, open-label, phase I, dose-escala-
tion study using a standard 3 3 design. Eligible patients had
a histologically confirmed diagnosis of incurable NSCLC
(defined as metastatic disease or the presence of malignant
pleural effusion) and a requirement for systemic antineoplas-
tic therapy. Additionally, patients had to be 18 years old or
older, have an Eastern Cooperative Oncology Group perfor-
mance status 2, and provide written informed consent.
Main exclusion criteria were defined as follows: absolute
granulocyte count 2000/L, platelet count 100,000/L,
aspartate aminotransferase and alanine aminotransferase 5
the upper normal limit (UNL), alkaline phosphatase 5
UNL, bilirubin more than the UNL, creatinine more than the
UNL, peripheral neuropathy grade 2, more than two pre-
vious cytotoxic regimens, known history of febrile neutrope-
nia with previous cytotoxic chemotherapy, and uncontrolled
hypertension. Patients previously treated with cisplatin and/or
docetaxel were eligible provided they met all other eligibility
criteria. Patients with brain metastases were eligible whether
or not they had received previous therapy for the brain
metastases and whether or not they were experiencing pro-
gression of brain metastases after previous therapy.
Patients on the initial cohort were treated with an
intravenous infusion of motexafin gadolinium 2.5 mg/kg over
30 minutes followed, after a 30-minute minimal interval, by
docetaxel 75 mg/m2 intravenously (IV) over 1 hour and
cisplatin 75 mg/m2 IV over 2 hours. Premedications for MGd
included oral hydration with at least 475 ml of a noncaffein-
ated, nonalcoholic beverage (or oral or intravenous hydration
with 500 to 1000 ml of fluids if the patients appeared
clinically dehydrated), and an antiemetic at the discretion of
the attending physician. Dexamethasone 8 mg by mouth was
given twice daily beginning 24 hours before the planned
docetaxel dose and continued for two doses the day after
treatment (for a total of six doses). Hydration (500–1000 ml
normal saline before and after cisplatin plus 1000 ml normal
saline with 25 g mannitol for cisplatin dilution) and anti-
emetic measures (dexamethasone 12–20 mg, diphenhydra-
mine 25 mg, ondansetron 8 mg aprepitant) were prescribed
per institutional protocol. Cycles were given every 3 weeks for
up to six cycles or until disease progression or occurrence of
DLT/intolerable toxicities. A maximal 2-week treatment delay
was allowed if patients did not meet adequate hematologic and
biochemistry parameters at the time of their scheduled chemo-
therapy. Dose reductions of MGd were not permitted.
Adverse events were graded using the National Cancer
Institute Common Terminology Criteria version 3. Response
evaluation was defined by the RECIST (Response Evaluation
Criteria in Solid Tumors).19
DLT was defined as any of the following occurring
during the first cycle of therapy: treatment-related grade 4
hematologic toxicity lasting 14 days or longer, febrile neu-
tropenia, thrombocytopenia-related bleeding, treatment-re-
lated absolute granulocyte count 1000/L or platelet count
100,000/L delaying administration of cycle 2 for 14 days
or longer (of note, colony-stimulating factors to treat asymp-
tomatic cytopenia were not permitted during cycle 1), treat-
ment-related clinically significant nonhematologic toxicity of
grade 3 or higher (with the exception of grade 3 or higher nausea
or vomiting and grade 3 fatigue), treatment-related grade 3 or 4
nausea or vomiting unresponsive to antiemetic treatment.
Cohorts of three patients per dose level were planned as
follows: cohort 1, MGd 2.5 mg/kg on day 1, docetaxel 75
mg/m2 on day 1, cisplatin 75 mg/m2 on day 1; cohort 2, MGd
5 mg/kg on day 1, docetaxel 75 mg/m2 on day 1, cisplatin 75
mg/m2 on day 1; cohort 3, MGd 10 mg/kg on day 1, docetaxel
75 mg/m2 on day 1, cisplatin 75 mg/m2 on day 1; cohort 4,
MGd 7.5 mg/kg on days 1 and 2, docetaxel 75 mg/m2 on day
1, cisplatin 75 mg/m2 on day 1. If no DLTs were observed,
the subsequent cohort was opened. In the event of occurrence
of 1 DLT among the first three patients, the cohort was expanded
to a total of six patients before opening the next cohort. If two or
more patients experienced a DLT in any given cohort, the MTD
would be established at the dose levels used in the cohort
immediately before. The only exception would be for cohort 3:
if two or more patients experienced a DLT, cohort 3A would be
opened (MGd 5 mg/kg on days 1 and 2, docetaxel 75 mg/m2 on
day 1, cisplatin 75 mg/m2 on day 1), before declaring an MTD
or proceeding to cohort 4.
The primary endpoints of the trial were to determine the
MTD and the DLTs of the combination of MGd, docetaxel,
and cisplatin in the study population. The secondary endpoint
was to evaluate the regimen’s objective response rate. Data on
survival and time to progression were also collected. Time to
endpoint events were calculated by the Kaplan-Meier method.
The study was approved by the institutional review
board and was conducted in accordance with the provisions
of the Declaration of Helsinki and Good Clinical Practice
guidelines.
RESULTS
Patient Characteristics
Twenty-two patients were enrolled in the trial; how-
ever, one patient was found to be ineligible due to previous
allergic reaction to carboplatin and was withdrawn from the
study without receiving the drugs. This patient was excluded
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from both safety and response evaluations. The remaining 21
patients were assessable for toxicity and 20 patients were
assessable for response. Their baseline characteristics are
described in Table 1.
Treatment Characteristics
Cohorts 1, 2, 3, and 4 were assigned three, six, seven,
and five patients, respectively. No patients were accrued for
cohort 3A. Number of cycles received, number of cycles
delayed, and the reason for treatment discontinuation for each
cohort are described in Table 2. Although not originally
allowed per protocol, one patient had the dose of cisplatin
reduced to 60 mg/m2 after cycle 1 due to a grade 1 creatinine
increase. Two patients had the doses of both cisplatin and
docetaxel reduced to 60 mg/m2 (after cycles 2 and 4, respec-
tively) due to neutropenic fever/nausea (cohort 2), and nau-
sea/vomiting/fatigue (cohort 4).
Tolerability and Safety
In the first cohort, three patients were treated and no
DLTs were observed. In the second cohort, one of the initial
three patients experienced a DLT (grade 3 neutropenic fever
after cycle 1). Three other patients were enrolled in this
cohort and no further DLTs were observed. However, two
patients experienced clinically meaningful adverse events
during the course of treatment that were not considered DLTs
because they did not occur during cycle 1, but prompted
chemotherapy termination: one patient had grade 4 neutro-
penic fever after cycles 3 and 5 and grade 3 hypertension after
cycle 5, and one patient had a grade 4 non-ST segment
elevation myocardial infarction after cycle 2.
In the third cohort, one of seven patients experienced a
DLT, consisting of a grade 5 myocardial ischemia and fluid
overload attributed, at first, to prehydration given before the
first cycle of chemotherapy and/or underlying hypercoagula-
ble state. Three patients were taken off study due to adverse
events not considered DLTs: two patients experienced grade
3 fatigue after one and three cycles, and one patient experi-
enced grade 2 nausea after four cycles. Other clinically
meaningful adverse events observed at this dose level in-
cluded grade 3 febrile neutropenia in one patient (after cycles
2 and 6) and grade 3 hypertension in one patient (after cycle
2). One other patient experienced sudden death of unknown
cause (no necropsy was performed) after cycle 4.
Three patients were initially enrolled in the fourth
cohort, with no DLTs observed. However, one patient termi-
nated the study after four cycles due to grade 3 nausea,
vomiting, and fatigue. A second patient had grade 3 hyper-
tension (230/130 mmHg) requiring interruption of treatment
after the first day of the second cycle and institution of
intravenous antihypertensive medication. Two additional pa-
tients were then treated at this same dose level. The first
patient had grade 3 hypertension and a grade 5 acute respi-
ratory distress syndrome of unknown cause (possibly due to
drug-induced pneumonitis, radiation pneumonitis, or infec-
tion) with an onset 6 days after the administration of the
first cycle of treatment. The second patient experienced
grade 3 neutropenic fever after one cycle. Due to the
occurrence of these two DLTs, it was decided to terminate
the study and declare the MTD at the dose level of cohort
3 (MGd 10 mg/kg, followed by docetaxel 75 mg/m2,
TABLE 1. Baseline Characteristics of Eligible Patients
Characteristic No. (%) of Patients (n  21)
Median age, yr (range) 52 (38–71)
Performance status
0 3 (14.3)
1 17 (81.0)
2 1 (4.8)
Sex
Female 8 (38.1)
Male 13 (61.9)
Histology
Non-small cell carcinoma, NOS 9 (42.9)
Adenocarcinoma 9 (42.9)
Squamous cell carcinoma 3 (14.3)
Stage
IV 21 (100)
Brain metastases
None 10 (47.6)
Previously untreated 2 (9.5)
Previously treated, controlled 6 (28.6)
Previously treated, uncontrolled 3 (14.3)
No. of prior systemic treatments
0 9 (42.9)
1 5 (23.8)
2 7 (33.3)
Previous systemic treatments
No platinum 11 (52.4)
Platinum 10 (47.6)
No taxanes 11 (52.4)
Paclitaxel 8 (38.1)
Docetaxel 2 (9.5)
NOS, not otherwise specified.
TABLE 2. Characteristics of the Treatment Received in Each
Cohort
Cohort
1 2 3 4
No. of patients 3 6 7 5
Total no. of cycles 13 17 21 14
Median no. of cycles/patient
(range)
5 (2–6) 2 (1–6) 3 (1–6) 2 (1–6)
No. (%) of cycles delayed 2 (15) 2 (12) 3 (14) 4 (29)
No. (%) of patients discontinuing
treatment due to
Completion of all six cycles 1 (33) 1 (17) 1 (14) 1 (20)
Occurrence of DLT 1 (17) 1 (14)a 2 (40)a
Other adverse events (not DLT) 2 (33) 3 (43) 2 (40)
Disease progression 1 (33) 2 (33) 1 (14)
Death (not treatment related) 1 (33) 1 (14)
DLT, dose-limiting toxicity.
a One patient in cohorts 3 and 4 experienced grade 5 DLT.
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followed by cisplatin 75 mg/m2 every 3 weeks). The DLTs
were neutropenic fever, myocardial ischemia, hyperten-
sion, and pneumonitis/pulmonary infiltrates (Table 3) and
occurred in two chemotherapy-naive patients (neutropenic
fever, myocardial ischemia) and two previously treated
patients (neutropenic fever, hypertension, pneumonitis/
pulmonary infiltrates).
The complete list of all grade 3–5 adverse events
observed throughout the four dose levels is presented in Table
4. The most common severe nonhematologic toxicities were
fatigue (five patients), followed by hypertension (four pa-
tients, one of them with a history of chronic hypertension),
nausea, vomiting, dehydration, and myocardial ischemia (two
patients each). Hypertension was usually acute and self-
limited, occurred within the first 24 hours of MGd adminis-
tration, and subsided after institution of oral clonidine. The
two episodes of myocardial ischemia observed also occurred
within the first 24 hours of MGd administration. The first
patient with myocardial ischemia was a 49-year-old former
smoker with a history of hypertension who experienced chest
pain during the infusion of cycle 2 docetaxel. Elevation of
cardiac enzymes and T-wave inversion on the electrocardio-
gram were documented, and the patient was treated with
aggressive medical management. No coronary artery cathe-
terization was performed due to the cancer-related poor
prognosis. The patient was discharged after stabilization and
remains in follow-up. The second patient was a 54-year-old
nonsmoker who experienced dyspnea 5 hours after comple-
tion of chemotherapy. At the time of hospital admission,
pulmonary edema was identified along with cardiac enzymes
TABLE 3. Worst Toxicities by Grade (3–5) per Patient at Each Dose Level during Cycle 1
Cohort 1
(n  3)
Cohort 2
(n  6)
Cohort 3
(n  7)
Cohort 4
(n  5)
Grade 3 4 5 3 4 5 3 4 5 3 4 5
Granulocytopenia 1 2 2 2
Febrile neutropeniaa 1 1
Myocardial infarctiona 1
Hypertensiona 1
Pneumonitis/pulmonary infiltratea 1
Nausea 1
Vomiting 1
Diarrhea 1
Dehydration 1
Fatigue 1 2
Hypomagnesemia 1
a Denotes dose-limiting toxicities.
TABLE 4. Worst Toxicities by Grade (3–5) per Patient at Each Dose Level during All Cycles
Cohort 1
(n  3)
Cohort 2
(n  6)
Cohort 3
(n  7)
Cohort 4
(n  5)
Grade 3 4 5 3 4 5 3 4 5 3 4 5
Granulocytopenia 1 2 2 3 1 2
Febrile neutropenia 1 1 1 1 1
Myocardial infarction 1 1
Hypertension 1 1 2
Pneumonitis/pulmonary infiltrate 1
Nausea 1 1
Vomiting 1 1
Diarrhea 1
Dehydration 1 1
Muscle weakness 1
Fatigue 3 2
Hearing (without monitoring) 1
Ocular/visual 1
Hyponatremia 1
Hypokalemia 1
Hypomagnesemia 1
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elevation and nonspecific ST segment alterations in the elec-
trocardiogram. The patient developed rapid clinical deterio-
ration and cardiogenic shock and died 17 hours after the
initial symptoms.
Efficacy
In the 21 assessable patients, overall response rates to
the treatment were as follows: no complete responses, two
partial responses (10%, confirmed), 12 stable diseases (60%,
two unconfirmed), and six disease progressions (30%).
Among the 11 patients with brain metastases, no discordance
was observed between responses in the brain and at other
sites of disease (three patients with disease progression, eight
patients with stable diseases). Among all 21 patients, five had
progression in the central nervous system before disease
progression at other sites. Of these five, four had had previous
cranial irradiation (two WBRT, two stereotactic radiosur-
gery) and two had had progression in the brain after cranial
irradiation before initiation of treatment in this trial. To date,
all patients have had disease progression and 11 patients
(52%) have died. Median overall survival was 7.3 months.
Median progression-free survival was 3.5 months, and me-
dian duration of response or stable disease was 4.2 months.
DISCUSSION
The first phase I trial of MGd in humans used the
strategy of escalating single-dose administration of the drug
during the first week of radiation in 38 patients with various
types of incurable cancers (13 cohorts with doses from 0.6
mg/kg to 29.6 mg/kg).1 This trial defined the MTD at 22.3
mg/kg IV once during the first week of radiation. The DLT
was reversible renal toxicity Subsequently, a phase Ib/II
multidose trial of MGd (0.3–8.4 mg/kg/day) administered
daily for 10 days before each fraction of WBRT was per-
formed.11 The MTD was determined at 6.3 mg/kg. The DLTs
were transient and self-limiting grade 4 liver function test
abnormalities and one cerebrovascular event at the dose of
8.4 mg/kg/day. Other serious adverse events were grade 3
hepatotoxicity, hypertension, and brain edema. Two patients
died of adverse events possibly related to the study drug (one
cerebral infarct and one ischemic bowel disease). In the phase
II part of the trial, the dose of 5.0 mg/kg was considered
optimal for the subsequent phase III studies.
In the two large phase III trials performed to date, MGd
was administered at the dose of 5.0 mg/kg/day before each
fraction of WBRT for 10 days. The most common adverse
events were skin discoloration, urine discoloration, and hy-
pertension. The most common grade 3–4 adverse events were
hypertension (4.0%–5.8%), fatigue (2.9%), asthenia (1.8%–
2.6%), liver enzyme abnormalities (2.6%), and hyponatremia
(2.1%).12,13
In the present phase I trial, MGd was administered in
combination with standard doses of cisplatin and docetaxel at
a starting dose 50% lower than the daily dose used in the
randomized trials with radiation and increased to 7.5 mg/kg
on days 1 and 2 of a 3-week cycle. Across all dose levels, the
most common grade 3–5 adverse events were granulocyto-
penia, febrile neutropenia, fatigue, hypertension, dehydration,
nausea, and vomiting. Except for hypertension, all these
toxicities could be attributed to chemotherapy alone and MGd
did not appear to have contributed significantly to the exac-
erbation of these side effects. This is in accordance with
another phase I trial of the combination of MGd and do-
cetaxel.20 However, in our study, two patients experienced
acute myocardial ischemia and one patient had a sudden
death of unknown cause, which raises the question whether
MGd might exhibit a prothrombotic effect. Although not
reported in the large phase III trials, in the early phase Ib/II
trial of MGd concomitant with WBRT, ischemic events
(bowel and cerebral ischemia) have also been documented11;
conversely, patients with lung cancer often have tobacco-
related underlying vascular disease, and the ischemic events
observed could be unrelated to the study drug. Furthermore,
hypertension has been commonly reported in the previous
phase III trials (any grade, 29.5%).12 In the present study,
four of 21 patients experienced grade 3 hypertension, usually
controlled with oral clonidine. It is unclear to what extent
hypertension could have contributed to the ischemic events/
sudden death observed and whether the combination of che-
motherapy and MGd leads to greater cardiovascular toxicity
than any of the agents alone. However, the high incidence of
cardiovascular side effects documented in the present study
warrants stringent selection criteria and careful observation of
patients exposed to these drugs, if this treatment strategy is to
be studied in future phase II trials.
Besides cardiovascular toxicity, febrile neutropenia and
pneumonitis/pulmonary infiltrates were the other DLTs iden-
tified. It is unclear whether the pneumonitis/pulmonary infil-
trates observed in one patient in cohort 4 were related to
MGd. That particular patient had received chemoradiation 5
weeks before chemotherapy initiation, and lung inflammation
due to previous radiotherapy, ongoing infection, or exposure
to docetaxel could not be excluded. To our knowledge, there
is only one other case of a potential grade 1–2 respiratory
toxicity of the combination of weekly MGd and docetaxel
described in the literature.21 Interestingly, in another phase I
trial of docetaxel (75 mg/m2) and MGd (10 mg/kg) three
times per week, radiation recall esophagitis was documented
and considered a DLT,20 and it is possible that the pulmonary
infiltrates observed in the patient enrolled in the present study
were a consequence of radiation recall pneumonitis.
Pharmacokinetic evaluation of MGd was not performed
in this study. However, data on MGd population pharmaco-
kinetics from 243 adults in three clinical trials has been
previously published and support a three-compartment intra-
venous model.22 Phenytoin, a cytochrome P-450 3A4, 5, or 7
inducer, increased MGd clearance by about 30%. However,
other 3A4, 5, or 7 inducers did not alter MGd clearance,
which may suggest that interaction between the two drugs
might occur through a different mechanism.22 Docetaxel is
also metabolized by cytochrome P-450 CYP 3A4 and CYP
3A5 subfamilies of isoenzymes and could present interactions
with MGd as well. Yet, the adverse events of docetaxel did
not seem to be exacerbated or improved in this study and in
a previous phase I trial,20 suggesting a lack of clinically
significant interactions between these two drugs. This, how-
ever, remains to be proven in studies specifically designed for
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this purpose. The selection of patients with adequate renal
function and close monitoring of creatinine throughout the
study period also argue against a pharmacologic interaction
between cisplatin and MGd.
The combination of MGd, docetaxel, and cisplatin was
active in patients with metastatic NSCLC. Due to the small
sample size and the heterogeneity of the population treated
(i.e., patients with performance status 0–2, presence and
absence of previous systemic treatment and different levels of
disease extension, including some patients with brain metas-
tases), it is unclear from this phase I trial whether MGd adds
to the antitumor activity of docetaxel and cisplatin. The
rationale for including previously treated patients in this trial
was to deliver a novel drug that had presented single-agent
preclinical activity and that would also theoretically enhance
any cytotoxic treatment that elicits perturbations in the tumor
cells redox system.7 As a result, patients not previously
exposed to platinum and/or docetaxel would still be receiving
active salvage treatment, whereas those previously treated
with both drugs (only one patient) could still, putatively,
benefit from MGd. The inclusion of these patients makes
interpretation of response rates equivocal. Nonetheless, this
was not the primary endpoint of the trial. Moreover, the
tolerability of the drug, the preclinical rationale, and the
efficacy of MGd in delaying neurologic deterioration in
patients with brain metastases from NSCLC treated with
radiation justifies further investigation of the combination of
MGd, docetaxel, and cisplatin in phase II trials. One clinical
scenario in which this drug regimen might play a role and
could potentially be evaluated in the future includes the
systemic treatment of patients with brain metastases from
NSCLC, preceding or following WBRT. The design and
conduct of such trials will depend on the U.S. Food and Drug
Administration ruling on the new drug application for MGd
in combination with WBRT for NSCLC. The doses of cis-
platin 75 mg/m2, docetaxel 75 mg/m2, and MGd 10 mg/kg IV
on day 1 every 3 weeks are recommended for subsequent
studies. However, consideration should be given to dose
reductions in patients at high risk of cardiovascular disease.
Adequate selection of patients, frequent cardiac assessment,
and aggressive management of hypertension are also strongly
suggested.
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